Analytical methods and formulation factors to enhance protein stability in solution

Archives of Pharmacal Research

Volumn 35, Issue 11, 2012, Pages 1871-1886

  Jeong, Seong Hoon ^a  

^a Dongguk University   (South Korea)

Author keywords

Analytical methods; Biopharmaceuticals; Formulation; Protein stability; Stability

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ARGININE; BASILIXIMAB; BEVACIZUMAB; CANAKINUMAB; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GOLIMUMAB; INFLIXIMAB; OFATUMUMAB; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; POLYMER; POLYOL; RANIBIZUMAB; RITUXIMAB; SUGAR; SURFACTANT; TOCILIZUMAB; TRASTUZUMAB; USTEKINUMAB;

CIRCULAR DICHROISM; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; ENVIRONMENTAL FACTOR; HUMAN; INFRARED SPECTROMETRY; PH; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SPECTROFLUOROMETRY; TEMPERATURE;

EID: 84874411132     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-1103-x     Document Type: Review

References (124)

1. Amidi, M.; Pellikaan, H. C.; De Boer, A. H.; Crommelin, D. J. A.; Hennink, W. E.; and Jiskoot, W.; Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery. Eur. J. Pharm. Biopharm.; 68, 191-200 (2008).
2. Arakawa, T.; Ejima, D.; Tsumoto, K.; Obeyama, N.; Tanaka, Y.; Kita, Y.; and Timasheff, S. N.; Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects. Biophys. Chem.; 127, 1-8 (2007).
3. Arakawa, T.; Kita, Y.; Ejima, D.; Tsumoto, K.; and Fukada, H.; Aggregation suppression of proteins by arginine during thermal unfolding. Protein Pept. Lett.; 13, 921-927 (2006).
4. Arakawa, T.; Prestrelski, S. J.; Kenney, W. C.; and Carpenter, J. F.; Factors affecting short-term and long-term stabilities of proteins. Adv. Drug Deliv. Rev.; 46, 307-326 (2001).
5. Arakawa, T. and Tsumoto, K.; The effects of arginine on refolding of aggregated proteins: not facilitate refolding, but suppress aggregation. Biochem. Biophys. Res. Commun.; 304, 148-152 (2003).
6. Aune, K.C. and Tanford, C.; Thermodynamics of the denaturation of lysozyme by guanidine hydrochloride. II. Dependence on denaturant concentration at 25 degrees. Biochemistry, 8, 4586-4590 (1969).
7. Azevedo, A.M.; Cabral, J. M. S.; Prazeres, D. M. F.; Gibson, T. D.; and Fonseca, L. P.; Thermal and operational stabilities of Hansenula polymorpha alcohol oxidase. J. Mol. Catal. B Enzym.; 27, 37-45 (2004).
8. Azuaga, A.I.; Dobson, C. M.; Mateo, P. L.; and Conejero-Lara, F.; Unfolding and aggregation during the thermal denaturation of streptokinase. Eur. J. Biochem.; 269, 4121-4133 (2002).
9. Bermudez, O. and Forciniti, D.; Aggregation and denaturation of antibodies: a capillary electrophoresis, dynamic light scattering, and aqueous two-phase partitioning study. J. Chromatogr. B, 807, 17-24 (2004).
10. Biltonen, R.L. and Lumry, R.; Chymotrypsinogen family of proteins. VII. Thermodynamic analysis of transition I of alpha.-chymotrypsin. J. Am. Chem. Soc.; 91, 4256-4264 (1969).
11. Bolen, D.W. and Baskakov, I. V.; The osmophobic effect: natural selection of a thermodynamic force in protein folding. J. Mol. Biol.; 310, 955-963 (2001).
12. Booth, D.R.; Sunde, M.; Bellotti, V.; Robinson, C. V.; Hutchinson, W. L.; Fraser, P. E.; Hawkins, P. N.; Dobson, C. M.; Radford, S. E.; Blake, C. C. F.; and Pepys, M. B.; Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature, 385, 787-793 (1997).
13. Brorson, K. and Phillips, J.; Defining your product profile and maintaining control over it, Part 4. Product-related impurities: tackling aggregates. Bioprocess Technical, 3, 50-54 (2005).
14. Bugamelli, F.; Raggi, M. A.; Orienti, I.; and Zecchi, V.; Controlled insulin release from chitosan microparticles. Arch. Pharm.; 331, 133-138 (1998).
15. Ca, O.; Spek, E. J.; Shi, Z.; Vologodskii, A.; and Kallenbach, N. R.; Cooperative helix stabilization by complex Arg-Glu salt bridges. Proteins, 44, 123-132 (2001).
16. Calamai, M.; Taddei, N.; Stefani, M.; Ramponi, G.; and Chiti, F.; Relative influence of hydrophobicity and net charge in the aggregation of two homologous proteins. Biochemistry, 42, 15078-15083 (2003).
17. Carpenter, J.F.; Prestrelski, S. J.; and Dong, A.; Application of infrared spectroscopy to development of stable lyophilized protein formulations. Eur. J. Pharm. Biopharm.; 45, 231-238 (1998).
18. Castellanos, I.J.; Carrasquillo, K. G.; Lopez, J. D.; Alvarez, M.; and Griebenow, K.; Encapsulation of bovine serum albumin in poly(lactide-co- glycolide) microspheres by the solid-in-oil-in-water technique. J. Pharm. Pharmacol.; 53, 167-178 (2001).
19. Chen, B.L.; Arakawa, T.; Hsu, E.; Narhi, L. O.; Tressel, T. J.; and Chien, S. L.; Strategies to suppress aggregation of recombinant keratinocyte growth factor during liquid formulation development. J. Pharm. Sci.; 83, 1657-1661 (1994a).
20. Chen, B.L.; Arakawa, T.; Morris, C. F.; Kenney, W. C.; Wells, C. M.; and Pitt, C. G.; Aggregation pathway of recombinant human keratinocyte growth factor and its stabilization. Pharm. Res.; 11, 1581-1587 (1994b).
21. Chi, E.Y.; Krishnan, S.; Randolph, T. W.; and Carpenter, J. F.; Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm. Res.; 20, 1325-1336 (2003).
22. Cleland, J. L. and Langer, R.; Formulation and delivery of proteins and peptides. American Chemicapl Society, ACS Symposium Series, Vol. 567, Chapter 1, pp. 1-19, (1994).
23. Cleland, J.L.; Powell, M. F.; and Shire, S. J.; The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Ctri. Rev. Ther. Drug, 10, 307-377 (1993).
24. Cromwell, M.E.; Hilario, E.; and Jacobson, F.; Protein aggregation and bioprocessing. AAPS J.; 8, E572-579 (2006).
25. Curatolo, L.; Valsasina, B.; Caccia, C.; Raimondi, G. L.; Orsini, G.; and Bianchetti, A.; Recombinant human IL-2 is cytotoxic to oligodendrocytes after in vitro self aggregation. Cytokine, 9, 734-739 (1997).
26. Dill, K. A.; Dominant forces in protein folding. Biochemistry, 29, 7133-7155 (1990).
27. Dong, A.; Kendrick, B.; Kreilgård, L.; Matsuura, J.; Manning, M. C.; and Carpenter, J. F.; Spectroscopic study of secondary structure and thermal denaturation of recombinant human factor XIII in aqueous solution. Arch. Biochem. Biophys.; 347, 213-220 (1997).
28. Dong, A.; Prestrelski, S. J.; Allison, S. D.; and Carpenter, J. F.; Infrared spectroscopic studies of lyophilization- and temperature-induced protein aggregation. J. Pharm. Sci.; 84, 415-424 (1995).
29. Faber-Barata, J. and Sola-Penna, M.; Opposing effects of two osmolytes - trehalose and glycerol - on thermal inactivation of rabbit muscle 6-phosphofructo-1-kinase. Mol. Cell. Biochem.; 269, 203-207 (2005).
30. Fan, H.; Ralston, J.; and Dibiase, M.; Solution behavior of IFN-α-1a: An empirical phase diagram based approach. J. Pharm. Sci.; 94, 1893-1911 (2005).
31. Fatouros, A.; sterberg, T.; and Mikaelsson, M.; Recombinant factor VIII SQ-influence of oxygen, metal ions, pH and ionic strength on its stability in aqueous solution. Int. J. Pharm.; 155, 121-131 (1997).
32. Fields, G.B.; Alonso, D. O. V.; Stigter, D.; and Dill, K. A.; Theory for the aggregation of proteins and copolymers. J. Phys. Chem.; 96, 3974-3981 (1992).
33. Fink, A.L.; Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold. Des.; 3, R9-R23 (1998).
34. Finke, J.M.; Roy, M.; Zimm, B. H.; and Jennings, P. A.; Aggregation events occur prior to stable intermediate formation during refolding of interleukin 1α. Biochemistry, 39, 575-583 (1999).
35. Fraser, P.E.; Mclachlan, D. R.; Surewicz, W. K.; Mizzen, C. A.; Snow, A. D.; Nguyen, J. T.; and Kirschner, D. A.; Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues. J. Mol. Biol.; 244, 64-73 (1994).
36. Garrett, R. H. and Grisham, C. M.; Biochemistry. Second edition ed, Saunders College Publishing, p. 1127, (1999).
37. Gonzalez, M.; Murature, D. A.; and Fidelio, G. D.; Thermal stability of human immunoglobulins with sorbitol: A critical evaluation. Vox Sang.; 68, 1-4 (1995).
38. Goolcharran, C.; Khossravi, M.; and Borchardt, R. T.; Chemical pathways of peptide degradation. X: effect of metalcatalyzed oxidation on the solution structure of a histidinecontaining peptide fragment of human relaxin. Pharm. Res.; 7, 851-858 (2000).
39. Graziano, G.; Catanzano, F.; Riccio, A.; and Barone, G.; A reassessment of the molecular origin of cold denaturation. J. Biochem.; 122, 395-401 (1997).
40. Greenfield, N.J.; Methods to estimate the conformation of proteins and polypeptides from circular dichroism data. Anal. Biochem.; 235, 1-10 (1996).
41. Gu, L.C.; Erdos, E. A.; Chiang, H. S.; Calderwood, T.; Tsai, K.; Visor, G. C.; Duffy, J.; Hsu, W. C.; and Foster, L. C.; Stability of interleukin 1 beta (IL-1 beta) in aqueous solution: analytical methods, kinetics, products, and solution formulation implications. Pharm. Res.; 8, 485-490 (1991).
42. Gupta, S. and Kaisheva, E.; Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques. AAPS PharmSci, 5, E8 (2003).
43. Ha, E.; Wang, W.; and Wang, Y. J.; Peroxide formation in polysorbate 80 and protein stability. J. Pharm. Sci.; 91, 2252-2264 (2002).
44. Haynie, D.T. and Freire, E.; Estimation of the folding/ unfolding energetics of marginally stable proteins using differential scanning calorimetry. Anal. Biochem.; 216, 33-41 (1994).
45. Hermeling, S.; Crommelin, D. J. A.; Schellekens, H.; and Jiskoot, W.; Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res.; 21, 897-903 (2004).
46. Huus, K.; Havelund, S.; Olsen, H. B.; Van De Weert, M.; and Frokjaer, S.; Thermal dissociation and unfolding of insulin. Biochemistry, 44, 11171-11177 (2005).
47. Ip, A.Y.; Arakawa, T.; Silvers, H.; Ransone, C. M.; and Niven, R. W.; Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization. J. Pharm. Sci.; 84, 1210-1214 (1995).
48. Israelachvili, J.; Intermolecular and Surface Forces, Academic Press, San Diego, California, (1992).
49. Istrail, S.; Schwartz, R.; and King, J.; Lattice simulations of aggregation funnels for protein folding. J. Comput. Biol.; 6, 143-162 (1999).
50. Jaenicke, R.; In Huber, R. and Winnackers, E. L. (Eds.) Protein Structure and Protein Engineering. Springer Verlag, Berlin, pp. 16-36, (1988).
51. Jaenicke, R.; Protein folding: local structures, domains, subunits, and assemblies. Biochemistry, 30, 3147-3161 (1991).
52. Jaenicke, R. and Rudolph, R.; In Creightons, T. E. (Ed.). Protein Structure: A Practical Approach. IRL Press, Oxford, pp. 191-223, (1989).
53. Jalalipour, M.; Gilani, K.; Tajerzadeh, H.; Najafabadi, A. R.; and Barghi, M.; Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents. Int. J. Pharm.; 352, 209-216 (2008).
54. Janis, J.; Rouvinen, J.; Leisola, M.; Turunen, O.; and Vainiotalo, P.; Thermostability of endo-1,4-beta-xylanase II from Trichoderma reesei studied by electrospray ionization Fourier-transform ion cyclotron resonance MS, hydrogen/deuterium-exchange reactions and dynamic light scattering. Biochem. J.; 356, 453-460 (2001).
55. Kauzmann, W. Some Factors in the Interpretation of Protein Denaturation. In C.B. Anfinsen, M. L. a. K. B.; and John, T. E. (Eds.) Advances in Protein Chemistry. Academic Press, pp. 1-63, (1959).
56. Kayed, R.; Head, E.; Thompson, J. L.; Mcintire, T. M.; Milton, S. C.; Cotman, C. W.; and Glabe, C. G.; Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300, 486-489 (2003).
57. Kendrick, B.S.; Carpenter, J. F.; Cleland, J. L.; and Randolph, T. W.; A transient expansion of the native state precedes aggregation of recombinant human interferongamma. Proc. Natl. Acad. Sci. U. S. A.; 95, 14142-14146 (1998).
58. Kerwin, B.A.; Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J. Pharm. Sci.; 97, 2924-2935 (2008).
59. Kerwin, B.A.; Akers, M. J.; Apostol, I.; Moore-Einsel, C.; Etter, J. E.; Hess, E.; Lippincott, J.; Levine, J.; Mathews, A. J.; Revilla-Sharp, P.; Schubert, R.; and Looker, D. L.; Acute and long-term stability studies of deoxy hemoglobin and characterization of ascorbate-induced modifications. J. Pharm. Sci.; 88, 79-88 (1999).
60. Kim, N.A.; An, I. B.; Lee, S. Y.; and Jeong, S. H.; Optimization of protein solution by a novel experimental design method using thermodynamic properties. Arch. Pharm. Res.; 35, 1609-1619 (2012).
61. Krishnamurthy, R. and Manning, M. C.; The stability factor: importance in formulation development. Curr. Pharm. Biotechnol.; 3, 361-371 (2002).
62. Krishnan, S.; Chi, E. Y.; Webb, J. N.; Chang, B. S.; Shan, D.; Goldenberg, M.; Manning, M. C.; Randolph, T. W.; and Carpenter, J. F.; Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. Biochemistry, 41, 6422-6431 (2002).
63. Lakowicz, J. R. and Joseph, R.; Principles of Fluorescence Spectroscopy. Plenum Press, New York, (1986).
64. Lange, C. and Rudolph, R.; Suppression of protein aggregation by L-arginine. Curr. Pharm. Biotechnol.; 10, 408-414 (2009).
65. Lin, J.J.; Meyer, J. D.; Carpenter, J. F.; and Manning, M. C.; Stability of human serum albumin during bioprocessing: denaturation and aggregation during processing of albumin paste. Pharm. Res.; 17, 391-396 (2000).
66. Linderstorm-Lang, K.; The ionization of proteins. Compt. Rend. Trav. Lab. Carlsberg, 29, 15-70 (1924).
67. Manning, M.C.; Patel, K.; and Borchardt, R. T.; Stability of protein pharmaceuticals. Pharm. Res.; 6, 903-918 (1989).
68. Mcphie, P.; Concentration-independent estimation of protein secondary structure by circular dichroism: a comparison of methods. Anal. Biochem.; 375, 379-381 (2008).
69. Mulkerrin, M.G. and Wetzel, R.; pH dependence of the reversible and irreversible thermal denaturation of gamma interferons. Biochemistry, 28, 6556-6561 (1989).
70. Nayar, R. and Manning, M. C.; High throughput formulation: strategies for rapid development of stable protein products. Pharm. Biotechnol.; 13, 177-98 (2002).
71. Nema, S.; Washkuhn, R. J.; and Brendel, R. J.; Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol.; 51, 166-171 (1997).
72. Nguyen, T. H. and Shire, S. J.; Stability and characterization of recombinant human relaxin. In Pearman, R. and Wangs, Y. J. (Eds.). Formulation, Characterization, and Stability of Protein Drugs. Plenum Press, New York, pp. 211-247, (1996).
73. Nielsen, L.; Frokjaer, S.; Brange, J.; Uversky, V. N.; and Fink, A. L.; Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry, 40, 8397-8409 (2001a).
74. Nielsen, L.; Frokjaer, S.; Carpenter, J. F.; and Brange, J.; Studies of the structure of insulin fibrils by Fourier transform infrared (FTIR) spectroscopy and electron microscopy. J. Pharm. Sci.; 90, 29-37 (2001b).
75. Nielsen, L.; Khurana, R.; Coats, A.; Frokjaer, S.; Brange, J.; Vyas, S.; Uversky, V. N.; and Fink, A. L.; Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry, 40, 6036-6046 (2001c).
76. Ohtake, S. and Wang, Y. J.; Trehalose: Current use and future applications. J. Pharm. Sci.; 100, 2020-2053 (2011).
77. Pace, C. N.; Conformational stability of globular proteins. Trends Biochem. Sci.; 15, 14-7 (1990).
78. Pace, C.N.; Shirley, B. A.; Mcnutt, M.; and Gajiwala, K.; Forces contributing to the conformational stability of proteins. FASEB J.; 10, 75-83 (1996).
79. Parkins, D.A. and Lashmar, U. T.; The formulation of biopharmaceutical products. Pharm. Sci. Technol. Today, 3, 129-137 (2000).
80. Poon, S.; Birkett, N. R.; Fowler, S. B.; Luisi, B. F.; Dobson, C. M.; and Zurdo, J.; Amyloidogenicity and aggregate cytotoxicity of human glucagon-like peptide-1 (hGLP-1). Protein Pept. Lett.; 16, 1548-1556 (2009).
81. Powell, M.F.; Nguyen, T.; and Baloian, L.; Compendium of excipients for parenteral formulations. PDA J. Pharm. Sci. Tech.; 52, 238-311 (1998).
82. Privalov, P. L.; Cold denaturation of proteins. Crit. Rev. Biochem. Mol. Biol.; 25, 281-305 (1990).
83. Privalov, P. L. and Gill, S. J.; Stability of Protein Structure and Hydrophobic Interaction. In C. B. Anfinsen, J. T. E. F. M. R.; and David, S. E. (Eds.). Advances in Protein Chemistry. Academic Press, pp. 191-234, (1988).
84. Querol, E.; Perez-Pons, J. A.; and Mozo-Villarias, A.; Analysis of protein conformational characteristics related to thermostability. Protein Eng.; 9, 265-271 (1996).
85. Reddy, K.R.; Lilie, H.; Rudolph, R.; and Lange, C.; Larginine increases the solubility of unfolded species of hen egg white lysozyme. Protein Sci.; 14, 929-935 (2005).
86. Remmele, R. L.; Bhat, S. D.; Phan, D. H.; and Gombotz, W. R.; Minimization of recombinant human Flt3 ligand aggregation at the Tm plateau: a matter of thermal reversibility. Biochemistry, 38, 5241-5247 (1999).
87. Rosenberg, A. S.; Effects of protein aggregates: an immunologic perspective. AAPS J.; 8, E501-507 (2006).
88. Rudolph, R. and Fischer, S.; Process for obtaining renatured proteins. US Patent 4,933,434 (1989).
89. Sanchez-Ruiz, J. M.; Theoretical analysis of Lumry-Eyring models in differential scanning calorimetry. Biophys. J.; 61, 921-935 (1992).
90. Sato, K.; Wakamiya, A.; Maeda, T.; Noguchi, K.; Takashima, A.; and Imahori, K.; Correlation among secondary structure, amyloid precursor protein accumulation, and neurotoxicity of amyloid beta(25-35) peptide as analyzed by single alanine substitution. J. Biochem. (Tokyo), 118, 1108-1111 (1995).
91. Sauerborn, M.; Brinks, V.; Jiskoot, W.; and Schellekens, H.; Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol. Sci.; 31, 53-59 (2010).
92. Sek, D. C.; Protein Formulations Containing Sorbitol. Wyeth, North Andover, MA, US, (2008).
93. Shahrokh, Z.; Eberlein, G.; and Wang, Y. J.; Probing the conformation of protein (bFGF) precipitates by fluorescence spectroscopy. J. Pharm. Biomed. Anal.; 12, 1035-1041 (1994).
94. Shen, C.L.; Scott, G. L.; Merchant, F.; and Murphy, R. M.; Light scattering analysis of fibril growth from the aminoterminal fragment beta(1-28) of beta-amyloid peptide. Biophys. J.; 65, 2383-2395 (1993).
95. Shiraki, K.; Kudou, M.; Fujiwara, S.; Imanaka, T.; and Takagi, M.; Biophysical effect of amino acids on the prevention of protein aggregation. J. Biochem. (Tokyo), 132, 591-595 (2002).
96. Shiraki, K.; Kudou, M.; Nishikori, S.; Kitagawa, H.; Imanaka, T.; and Takagi, M.; Arginine ethylester prevents thermal inactivation and aggregation of lysozyme. Eur. J. Biochem.; 271, 3242-3247 (2004).
97. Sinko, P. J.; Chapter 2: States of Matter. Martin's Physical Pharmacy and Pharmaceutical Sciences. Lippincott Williams & Wilkins, Philadelphia, p. 795, (2006).
98. Soto, C.; Castano, E. M.; Frangione, B.; and Inestrosa, N. C.; The alpha-helical to beta-strand transition in the aminoterminal fragment of the amyloid beta-peptide modulates amyloid formation. J. Biol. Chem.; 270, 3063-3067 (1995).
99. Southall, N.T.; Dill, K. A.; and Haymet, A. D. J.; A View of the Hydrophobic Effect. J. Phys. Chem. B, 106, 521-533 (2001).
100. Stellwagen, E.; Park, S. H.; Shalongo, W.; and Jain, A.; The contribution of residue ion pairs to the helical stability of a model peptide. Biopolymers, 32, 1193-1200 (1992).
101. Stigter, D. and Dill, K. A.; Theory for protein solubilities. Fluid Phase Equilib.; 82, 237-249 (1993).
102. Szabó, Z.; Klement, Jost, K.; Zarándi, M.; Soós, K.; and Penke, B.; An FT-IR study of the beta-amyloid conformation: standardization of aggregation grade. Biochem. Biophys. Res. Commun.; 265, 297-300 (1999).
103. Tamber, H.; Johansen, P.; Merkle, H. P.; and Gander, B.; Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev.; 57, 357-376 (2005).
104. Teschke, C.M.; Aggregation and assembly of phage P22 temperature- sensitive coat protein mutants in vitro mimic the in vivo phenotype. Biochemistry, 38, 2873-2881 (1999).
105. Tischer, A.; Lilie, H.; Rudolph, R.; and Lange, C.; L-Arginine hydrochloride increases the solubility of folded and unfolded recombinant plasminogen activator rPA. Protein Sci.; 19, 1783-1795 (2010).
106. Tiwari, A. and Bhat, R.; Stabilization of yeast hexokinase A by polyol osmolytes: Correlation with the physicochemical properties of aqueous solutions. Biophys. Chem.; 124, 90-99 (2006).
107. Tomski, S.J. and Murphy, R. M.; Kinetics of aggregation of synthetic beta-amyloid peptide. Arch. Biochem. Biophys.; 294, 630-638 (1992).
108. Townsend, M.W. and DeLuca, P. P.; Stability of ribonuclease A in solution and the freeze-dried state. J. Pharm. Sci.; 79, 1083-1086 (1990).
109. Tsai, A.M.; Van Zanten, J. H.; and Betenbaugh, M. J. I.; Study of protein aggregation due to heat denaturation: A structural approach using circular dichroism spectroscopy, nuclear magnetic resonance, and static light scattering. Biotechnol. Bioeng.; 59, 273-280 (1998a).
110. Tsai, A.M.; Van Zanten, J. H.; and Betenbaugh, M. J.; 2nd.; Electrostatic effect in the aggregation of heat-denatured RNase A and implications for protein additive design. Biotechnol. Bioeng.; 59, 281-285 (1998b).
111. Tsumoto, K.; Ejima, D.; Kita, Y.; and Arakawa, T.; Review: Why is arginine effective in suppressing aggregation? Protein Pept. Lett.; 12, 613-619 (2005).
112. Tsumoto, K.; Umetsu, M.; Kumagai, I.; Ejima, D.; Philo, J. S.; and Arakawa, T.; Role of arginine in protein refolding, solubilization, and purification. Biotechnol. Prog.; 20, 1301-1308 (2004).
113. Vermeer, A.W. P.; and Norde, W.; The thermal stability of immunoglobulin: unfolding and aggregation of a multidomain protein. Biophys. J.; 78, 394-404 (2000).
114. Vrkljan, M.; Foster, T. M.; Powers, M. E.; Henkin, J.; Porter, W. R.; Staack, H.; Carpenter, J. F.; and Manning, M. C.; Thermal stability of low molecular weight urokinase during heat treatment. II. Effect of polymeric additives. Pharm. Res.; 11, 1004-1008 (1994).
115. Wang, W.; Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm.; 185, 129-188 (1999).
116. Wang, W.; Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm.; 289, 1-30 (2005).
117. Wang, Y.J. and Hanson, M. A.; Parenteral formulations of proteins and peptides: stability and stabilizers. J. Parent. Sci. Technol.; p. 42S, (1988).
118. Warne, N. W.; Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. Eur. J. Pharm. Biopharm.; 78, 208-212 (2011).
119. Warshel, A. and Levitt, M.; Theoretical studies of enzymic reactions: Dielectric, electrostatic and steric stabilization of the carbonium ion in the reaction of lysozyme. J. Mol. Biol.; 103, 227-249 (1976).
120. Wilkins, D.K.; Grimshaw, S. B.; Receveur, V.; Dobson, C. M.; Jones, J. A.; and Smith, L. J.; Hydrodynamic radii of native and denatured proteins measured by pulse field gradient NMR techniques. Biochemistry, 38, 16424-16431 (1999).
121. Won, C. M.; Molnar, T. E.; Mckean, R. E.; and Spenlehauer, G. A.; Stabilizers against heat-induced aggregation of RPR 114849, an acidic fibroblast growth factor (aFGF). Int. J. Pharm.; 167, 25-36 (1998).
122. Yancey, P.H.; Clark, M. E.; Hand, S. C.; Bowlus, R. D.; and Somero, G. N.; Living with water stress: evolution of osmolyte systems. Science, 217, 1214-1222 (1982).
123. Zhang, H.; Saiani, A.; Guenet, J.-M.; and Curtis, R.; Effect of stereoregular polyelectrolyte on protein thermal stability. Macromol. Symp.; 251, 25-32 (2007).
124. Zlateva, T.; Boteva, R.; Salvato, B.; and Tsanev, R.; Factors affecting the dissociation and aggregation of human interferon gamma. Int. J. Biol. Macromol.; 26, 357-362 (1999).